Increases capabilities and capacity to provide anti-infective testing, assay development and biomaterial production services for highly infectious pathogens.
Aims to provide improved product tracking, scheduling and live monitoring of the manufacturing status across the entire CGT supply chain from vein to vein.
Bamlanivimab and etesevimab agreement modified to enable the supply of etesevimab to complement doses of bamlanivimab the U.S. government already purchased.